Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.77 |
| ▸ | PPARG | P37231 | 1/20 | 0.77 |
| ▸ | CA12 | O43570 | 4/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA7 | P43166 | 4/20 | 0.53 |
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | SHBG | P04278 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12255054 | 1.00 | MEN1 (0.77) | MEN1KMT2ACYP3A4MAPTPPARG | |
| SCHEMBL9407198 | 0.90 | MEN1 (0.68) | MEN1KMT2ACYP3A4MAPTPPARG | |
| SCHEMBL3059351 | 0.88 | KMT2A (0.67) | MEN1KMT2ACYP3A4MAPTPPARG | |
| Angolensin (R) SCHEMBL30591540 | 0.88 | CYP3A4 (1.00) | MEN1KMT2ACYP3A4MAPTPPARG | |
| Angolensin (R) SCHEMBL2544863 | 0.88 | CYP3A4 (1.00) | MEN1KMT2ACYP3A4MAPTPPARG | |
| Angolensin (R) SCHEMBL12998482 | 0.88 | CYP3A4 (1.00) | MEN1KMT2ACYP3A4MAPTPPARG | |
| SCHEMBL3059363 | 0.86 | CYP3A4 (0.59) | MEN1KMT2ACYP3A4MAPTPPARG | |
| SCHEMBL13090314 | 0.85 | MEN1 (0.63) | MEN1KMT2ACYP3A4MAPTPPARG | |
| SCHEMBL24995123 | 0.81 | CYP3A4 (0.79) | MEN1KMT2ACYP3A4MAPTPPARG | |
| SCHEMBL1830213 | 0.81 | CA12 (0.59) | MEN1KMT2ACYP3A4MAPTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170166-A1 | HYALURONIC ACID HYDROGEL FORMULATION COMPRISING PHYTOESTROGEN FOR THE TREATMENT OF VAGINAL ATROPHY AND VAGINAL REJUVENATION AND PRODUCTION METHOD THEREOF | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2025-05-29 | — | — | US | claimed |
| EP-4482581-A1 | HYALURONIC ACID HYDROGEL FORMULATION COMPRISING PHYTOESTROGEN FOR THE TREATMENT OF VAGINAL ATROPHY AND VAGINAL REJUVENATION AND PRODUCTION METHOD THEREOF | VSY Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi (TR) | 2025-01-01 | — | — | EP | claimed |
| WO-2023163675-A1 | HYALURONIC ACID HYDROGEL FORMULATION COMPRISING PHYTOESTROGEN FOR THE TREATMENT OF VAGINAL ATROPHY AND VAGINAL REJUVENATION AND PRODUCTION METHOD THEREOF | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2023-08-31 | — | — | WO | claimed |
| US-20250351853-A1 | FOOD COMPOSITION COMPRISING EQUOL AND PRODUCTION METHOD THEREFOR | DAICEL CORPORATION (JP) | 2025-11-20 | — | — | US | disclosed |
| US-20250170166-A1 | HYALURONIC ACID HYDROGEL FORMULATION COMPRISING PHYTOESTROGEN FOR THE TREATMENT OF VAGINAL ATROPHY AND VAGINAL REJUVENATION AND PRODUCTION METHOD THEREOF | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2025-05-29 | — | — | US | disclosed |
| WO-2025028427-A1 | EQUOL-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME | 株式会社ダイセル | 2025-02-06 | — | — | WO | disclosed |
| EP-4482581-A1 | HYALURONIC ACID HYDROGEL FORMULATION COMPRISING PHYTOESTROGEN FOR THE TREATMENT OF VAGINAL ATROPHY AND VAGINAL REJUVENATION AND PRODUCTION METHOD THEREOF | VSY Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi (TR) | 2025-01-01 | — | — | EP | disclosed |
| US-20240091279-A1 | COMBINATION THERAPY FOR INFLAMMATORY DISEASES | NATIONAL INSTITUTES OF HEALTH | 2024-03-21 | — | — | US | disclosed |
| WO-2024059282-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023230574-A1 | ENGINEERED PHENYLALANINE AMMONIA LYASE AND TYROSINE AMMONIA LYASE ENZYMES FOR PRODUCING AROMATIC COMPOUNDS | GINKGO BIOWORKS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023224086-A1 | FOOD COMPOSITION COMPRISING EQUOL AND PRODUCTION METHOD THEREFOR | 株式会社ダイセル | 2023-11-23 | — | — | WO | disclosed |
| US-20080287528-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2008-11-20 | — | — | US | disclosed |
| US-7419998-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-02 | — | — | US | disclosed |
| US-7419998-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-02 | — | — | US | disclosed |
| EP-1927352-A2 | Therapeutic methods and compositions involving isoflavones | Novogen Research Pty. Ltd. (AU) | 2008-06-04 | — | — | EP | disclosed |
| WO-2008052256-A1 | PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | NOVOGEN RESEARCH PTY LTD (AU) | 2008-05-08 | — | — | WO | disclosed |
| US-20080069900-A1 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD | 2008-03-20 | — | — | US | disclosed |
| US-20080069900-A1 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD | 2008-03-20 | — | — | US | disclosed |
| US-7202273-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2007-04-10 | — | — | US | disclosed |
| US-7202273-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287528-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | C1R, ESRRA, ESRRB | MEN1 3266/4885KMT2A 3320/4885CYP3A4 1461/4885 |
| US-20080069900-A1 | Combination chemotherapy compositions and methods | TOP2A, IDH2, DHFR | MEN1 1073/4885KMT2A 1534/4885CYP3A4 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.